IGMS Stock - IGM Biosciences, Inc.
Unlock GoAI Insights for IGMS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.68M | $2.13M | $1.07M | N/A | N/A |
| Gross Profit | $-6,433,000 | $-6,147,000 | $-9,533,000 | $-7,724,000 | $-3,576,000 |
| Gross Margin | -240.1% | -288.6% | -891.8% | N/A | N/A |
| Operating Income | $-208,580,000 | $-263,461,000 | $-227,956,000 | $-165,323,000 | $-83,280,000 |
| Net Income | $-195,795,000 | $-246,416,000 | $-214,248,000 | $-160,680,000 | $-80,330,000 |
| Net Margin | -7308.5% | -11568.8% | -20041.9% | N/A | N/A |
| EPS | $-3.24 | $-4.71 | $-5.16 | $-4.80 | $-2.61 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 10th 2025 | BMO Capital Markets | Downgrade | Market Perform | $2← $21 |
| January 10th 2025 | Morgan Stanley | Downgrade | Underweight | $2← $12 |
| January 10th 2025 | Stifel | Downgrade | Hold | $2.5← $27 |
| January 10th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $1.5← $20 |
| January 10th 2025 | Guggenheim | Downgrade | Neutral | - |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $21 |
| October 1st 2024 | JP Morgan | Downgrade | Underweight | $9← $12 |
| October 1st 2024 | Truist | Downgrade | Hold | $12← $24 |
| February 9th 2024 | RBC Capital Mkts | Upgrade | Outperform | $21← $9 |
| December 15th 2023 | BofA Securities | Downgrade | Neutral | $8 |
| December 7th 2023 | H.C. Wainwright | Downgrade | Neutral | $7← $11 |
| November 9th 2022 | Jefferies | Resumed | Buy | $55← $61 |
| October 17th 2022 | JP Morgan | Initiation | Neutral | $27 |
| August 29th 2022 | BofA Securities | Initiation | Buy | $34 |
Earnings History & Surprises
IGMSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 31, 2025 | $-0.30 | $1.58 | +626.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.41 | $-0.86 | -109.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.45 | $-0.61 | -34.6% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.82 | $-1.01 | -23.2% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.04 | $-0.79 | -1991.1% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.84 | $-0.83 | +1.2% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-1.06 | $-1.01 | +4.7% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-1.25 | $-1.04 | +16.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.43 | $-1.43 | 0.0% | = MET |
Q2 2023 | May 12, 2023 | $-1.37 | $-1.33 | +2.9% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.53 | $-1.19 | +22.2% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.45 | $-1.32 | +9.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.44 | $-1.33 | +7.6% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-1.65 | $-1.53 | +7.3% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-1.58 | $-1.50 | +5.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-1.34 | $-1.32 | +1.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.21 | $-1.16 | +4.1% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.98 | $-0.95 | +3.1% | ✓ BEAT |
Q1 2021 | Mar 30, 2021 | $-0.74 | $-0.79 | -6.8% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-0.67 | $-0.58 | +13.4% | ✓ BEAT |
Frequently Asked Questions about IGMS
What is IGMS's current stock price?
What is the analyst price target for IGMS?
What sector is IGM Biosciences, Inc. in?
What is IGMS's market cap?
Does IGMS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IGMS for comparison